Recursion Pharmaceuticals vs Insitro

By valuation, Insitro is the larger company at $2.2B versus $1.8B — a 1.2x difference. Size can also be measured by team: Recursion Pharmaceuticals employs 800 people while Insitro has 300 employees.

Insitro has raised $743M in disclosed funding across 3 known rounds. Recursion Pharmaceuticals's funding history is not publicly available.

Insitro leads with an Awaira Score of 73/100, while Recursion Pharmaceuticals sits at 65/100. That 8-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Recursion Pharmaceuticals was founded by Chris Gibson in 2013. Insitro was founded by Daphne Koller in 2018. Visit each company's profile on Awaira for a full founder biography.

Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, using its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed. Insitro: Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data, predict drug efficacy and safety profiles, and optimize candidate selection across therapeutic areas including metabolic disease, oncology, and immunology. The company has raised $743 million across multiple funding rounds, achieving a valuation of $2.2 billion as of its Series C stage. This positions Insitro among well-capitalized AI healthcare startups addressing the structural inefficiencies in drug discovery. The company partners with pharmaceutical institutions to apply its technology to their pipelines, utilizing both internal discovery programs and collaborations. Insitro's competitive approach differs from pure software platforms by integrating experimental validation, reducing the translation gap between computational predictions and real-world drug performance. The company operates in a crowded but expanding market of AI drug discovery platforms competing against both established pharma AI initiatives and other venture-backed startups. Its growth trajectory reflects investor confidence in AI-enabled drug discovery models, though clinical validation remains ongoing for internally developed candidates. Insitro uniquely combines machine learning with integrated wet-lab capabilities rather than operating as pure software, bridging computational predictions to experimental validation.

Recursion Pharmaceuticals got there first, launching in 2013 — that's 5 years of extra runway. Insitro didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Recursion Pharmaceuticals has about 800 employees; Insitro has about 300. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Recursion Pharmaceuticals and Insitro compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.